Heart failure with preserved ejection fraction is common in people with type 2 diabetes but is often hard to recognize. Treatments newly proven to be effective make diagnosis an imperative.
With an essential role established for SGLT2 inhibitors for patients with progressive renal dysfunction or heart failure, researchers discuss how best to use these agents in those with type 2 diabetes.